Scinovex
review Open AccessTop 1% cited

Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis

Journal of Clinical Medicine · 2020 · Vol. 9(4) · pp. 941–941
Israel Júnior Borges do NascimentoNensi ĆaćićHebatullah Mohamed AbdulazeemThilo von GrooteUmesh JayarajahIshanka WeerasekaraMeisam Abdar EsfahaniVinicius Tassoni CivileAna MarušićAna JerončićNelson CarvasTina Poklepović PeričićIrena Zakarija‐GrkovićSilvana Mangeon Meirelles GuimarãesNicola Luigi BragazziMaria BjörklundAhmad Sofi‐MahmudiMohammad AltujjarMaoyi TianDiana Maria Cespedes ArcaniDónal P O’MathúnaMilena Soriano Marcolino

Abstract

A growing body of literature on the 2019 novel coronavirus (SARS-CoV-2) is becoming available, but a synthesis of available data has not been conducted. We performed a scoping review of currently available clinical, epidemiological, laboratory, and chest imaging data related to the SARS-CoV-2 infection. We searched MEDLINE, Cochrane CENTRAL, EMBASE, Scopus and LILACS from 01 January 2019 to 24 February 2020. Study selection, data extraction and risk of bias assessment were performed by two independent reviewers. Qualitative synthesis and meta-analysis were conducted using the clinical and laboratory data, and random-effects models were applied to estimate pooled results. A total of 61 studies were included (59,254 patients). The most common disease-related symptoms were fever (82%, 95% confidence interval (CI) 56%-99%; <i>n</i> = 4410), cough (61%, 95% CI 39%-81%; <i>n</i> = 3985), muscle aches and/or fatigue (36%, 95% CI 18%-55%; <i>n</i> = 3778), dyspnea (26%, 95% CI 12%-41%; <i>n</i> = 3700), headache in 12% (95% CI 4%-23%, <i>n</i> = 3598 patients), sore throat in 10% (95% CI 5%-17%, <i>n</i> = 1387) and gastrointestinal symptoms in 9% (95% CI 3%-17%, <i>n</i> = 1744). Laboratory findings were described in a lower number of patients and revealed lymphopenia (0.93 × 10<sup>9</sup>/L, 95% CI 0.83-1.03 × 10<sup>9</sup>/L, <i>n</i> = 464) and abnormal C-reactive protein (33.72 mg/dL, 95% CI 21.54-45.91 mg/dL; <i>n</i> = 1637). Radiological findings varied, but mostly described ground-glass opacities and consolidation. Data on treatment options were limited. All-cause mortality was 0.3% (95% CI 0.0%-1.0%; <i>n</i> = 53,631). Epidemiological studies showed that mortality was higher in males and elderly patients. The majority of reported clinical symptoms and laboratory findings related to SARS-CoV-2 infection are non-specific. Clinical suspicion, accompanied by a relevant epidemiological history, should be followed by early imaging and virological assay.

COVID-19 Clinical Research StudiesCOVID-19 diagnosis using AILong-Term Effects of COVID-19MedicineSore throatMeta-analysisConfidence intervalInternal medicineCoronavirus disease 2019 (COVID-19)EpidemiologyMEDLINESurgeryDisease
Citations
656
FWCI
15.05
field-weighted impact
References
96
Percentile
99%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis · Scinovex